Advances in Hematology

Unanswered Questions in HIV Hematology

Publishing date
25 May 2012
Submission deadline
06 Jan 2012

1Division of Hematology, St. Paul's Hospital and the University of British Columbia, 440–1144 Burrard Street, Vancouver, BC, Canada

2Centre for Lymphoma, Massachusetts General Hospital Cancer Centre, Harvard Medical School, Boston, MA, USA

3Division of Hematology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

4Division of Hematology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

Unanswered Questions in HIV Hematology


Patients with hematological abnormalities in HIV infection are seen regularly in the clinical setting. Malignant lymphomas, including aggressive forms of non-Hodgkin lymphoma (NHL), although decreased in incidence in the era of highly active antiretroviral therapy (HAART), are regularly seen and treated, as are other lymphoproliferative disorders such as Hodgkin lymphoma (HL), indolent NHL, Castleman disease, and paraproteinemias. Other blood disorders which occur with regularity include cytopenias, particularly anemia and thrombocytopenia, and immune thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP).

In this issue, we invite studies investigating hematologic diseases associated with HIV. Papers examining the epidemiology, clinical characteristics, predisposing factors, treatment, complications, and treatment outcomes will be considered. Review articles are welcome as are articles outlining guidelines for management. Topics of interest include, but are not limited to:

  • Treatment regimens and outcomes for HIV-NHL and HL
  • Role of immunotherapy in HIV-NHL
  • Toxicity of lymphoma chemo-immunotherapy
  • Role of high-dose chemotherapy and stem cell transplant in HIV-lymphoma
  • Chemotherapy-HAART interactions
  • Natural history, treatment, and outcome of indolent lymphoproliferative disorders and paraproteinemias
  • Natural history, treatment, and outcome of non-clonal lymphoproliferative disorders
  • Incidence, treatment, and outcome of HIV-ITP
  • Incidence, treatment, and outcome of HIV-TTP
  • Approach to HIV associated anemia

Before submission authors should carefully read over the journal's Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:


  • Special Issue
  • - Volume 2012
  • - Article ID 907025
  • - Editorial

Unanswered Questions in HIV Hematology

Heather A. Leitch | Jeremy S. Abramson | ... | Lisa K. Hicks
  • Special Issue
  • - Volume 2012
  • - Article ID 910954
  • - Research Article

Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era

Kimberley L. S. Ambler | Linda M. Vickars | ... | Heather A. Leitch
  • Special Issue
  • - Volume 2012
  • - Article ID 403648
  • - Review Article

Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma

Adam M. Petrich | Joseph A. Sparano | Samir Parekh
  • Special Issue
  • - Volume 2012
  • - Article ID 932658
  • - Review Article

Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings

Matthew Ulrickson | Oliver W. Press | Corey Casper
  • Special Issue
  • - Volume 2012
  • - Article ID 507257
  • - Review Article

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART

Caron A. Jacobson | Jeremy S. Abramson
  • Special Issue
  • - Volume 2012
  • - Article ID 735392
  • - Clinical Study

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

J. A. Rodrigo | L. K. Hicks | ... | H. A. Leitch
Advances in Hematology
 Journal metrics
Acceptance rate8%
Submission to final decision77 days
Acceptance to publication25 days
Journal Citation Indicator-
Impact Factor-

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.